Prometheus Struck Down by the Gods … | GenomeWeb

The US Supreme Court has overturned two methods patents on drug dose calibration held by biotech company Prometheus Laboratories, reports The Scientist's Sabrina Richards. The company's patents concerned the calibration of synthetic thiopurines, which are used to treat auto-immune diseases like Crohn's disease, Richards says. "Prometheus's methods rely on monitoring the levels of various metabolites in red blood cells," she adds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.